Novartis strengthens IgAN position with Fabhalta trial results: GlobalData EP News Bureau Oct 24, 2025 Positive Phase III data positions Novartis for stronger regulatory and commercial momentum in the IgA nephropathy treatment…
Novartis’ kidney disease drug Fabhalta receives US FDA approval EP News Bureau Aug 8, 2024 Fabhalta specifically targets the alternative complement pathway of the immune system. When overly activated in the kidneys, the…
